decisionhealth Newsletters, Part B News - 2013 Issue 9 (September)
Some big drugs see big changes in Q4, but most stay stable
Subscribe or sign in to view the full article.
Article Overview
This article summarizes CMS’s fourth-quarter average sales price update for Medicare Part B drugs and related payment limits. It is aimed at coding, billing, and reimbursement professionals who need to understand how quarterly drug price changes may affect provider payment and reimbursement workflows. The piece covers the overall market trend, the extent of CMS updates, and examples of larger upward and downward price movements across drugs, biologics, and related items.
Why This Topic Matters
Quarterly drug pricing updates can affect reimbursement, charge capture, and budgeting for practices that administer Part B drugs. Understanding which items moved materially helps revenue cycle and coding teams monitor payment impacts.
What You Will Learn
- How CMS describes the overall direction of the Q4 ASP update
- What categories of drugs and related items experienced notable price movement
- How quarterly payment limits can affect provider reimbursement context
- Which broad types of products were among the largest upward and downward movers
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Practice managers
- Pharmacy reimbursement professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com